BCL2 and cancer: The results of several phase I and phase I/II trials of G3139 have been reported [71, 72], showing that Bcl-2 As therapy resulted in the specific downregulation of Bcl-2, without significant toxicity at clinically relevant doses, and therefore has potential for the treatment of cancers, which have Bcl-2 over-expression, resistant to conventional therapy.